FindTrial
Sign In

20-valent pneumococcal conjugate vaccine

BIOLOGICAL10 trials

Sponsors

Pfizer, University of Alabama at Birmingham

Conditions

Alpha 1-AntitrypsinAntibody DeficiencyCOPDPneumococcal DiseaseStreptococcus Pneumoniae

Phase 1

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
Active, not recruitingNCT07086677
PfizerStreptococcus Pneumoniae
Start: 2025-07-22End: 2027-10-21Updated: 2026-06-22

Phase 3

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
CompletedNCT04379713
PfizerPneumococcal Disease
Start: 2020-05-21End: 2022-08-31Updated: 2023-06-13
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
CompletedNCT04382326
PfizerPneumococcal Disease
Start: 2020-05-20End: 2022-09-02Updated: 2023-12-06
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
CompletedNCT04530838
PfizerPneumococcal Disease
Start: 2020-09-16End: 2022-04-02Updated: 2023-04-21
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
CompletedNCT04546425
PfizerPneumococcal Disease
Start: 2020-09-09End: 2023-02-18Updated: 2024-01-08
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
CompletedNCT05408429
PfizerPneumococcal Disease
Start: 2022-06-24End: 2023-06-01Updated: 2024-09-19
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
CompletedNCT05512819
PfizerPneumococcal Disease
Start: 2022-09-16End: 2025-09-20Updated: 2025-12-15
A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.
CompletedNCT05875727
PfizerPneumococcal Disease
Start: 2023-08-16End: 2023-10-02Updated: 2024-10-24

Phase 4

Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
RecruitingNCT07135427
University of Alabama at BirminghamAlpha 1-Antitrypsin, Antibody Deficiency, COPD
Start: 2025-09-03End: 2027-06-30Target: 30Updated: 2025-11-07

Unknown Phase

A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
Active, not recruitingNCT06622109
PfizerPneumococcal Disease
Start: 2024-11-25End: 2026-12-15Updated: 2026-03-12

Related Papers

Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial.
2026-01-07
Safety and Immunogenicity of 20-Valent PCV According to Number and Timing of Primary Series Doses
2026-01-02
Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine–naive adults ≥18 years of age in India: A phase 3 single-arm trial
2026-01-01
Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine–naive adults ≥18 years of age in India: A phase 3 single-arm trial
2026-01-01
Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants.
2025-11-03
A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine
Vaccine2025-03-124 citations
A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
The Pediatric Infectious Disease Journal2024-03-2637 citations
Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers
The Pediatric Infectious Disease Journal2024-03-0825 citations
A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants.
2024-01-173 citations
1728. Immune Responses to Cross-Reactive Serotypes 6C and 15C After 20-Valent Pneumococcal Conjugate Vaccine in Infants
Open Forum Infectious Diseases2023-11-274 citations
An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants
Expert Review of Vaccines2023-10-176 citations